- Home
- EDIT vs GNFT Comparison
EDIT vs GNFT Comparison
Compare EDIT & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- GNFT
- Stock Information
- Founded
- EDIT 2013
- GNFT 1999
- Country
- EDIT United States
- GNFT France
- Employees
- EDIT N/A
- GNFT N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDIT Health Care
- GNFT Health Care
- Exchange
- EDIT Nasdaq
- GNFT Nasdaq
- Market Cap
- EDIT 179.1M
- GNFT 186.3M
- IPO Year
- EDIT 2016
- GNFT 2019
- Fundamental
- Price
- EDIT $2.88
- GNFT $3.75
- Analyst Decision
- EDIT Buy
- GNFT Strong Buy
- Analyst Count
- EDIT 12
- GNFT 1
- Target Price
- EDIT $6.20
- GNFT $13.00
- AVG Volume (30 Days)
- EDIT 3.5M
- GNFT 3.8K
- Earning Date
- EDIT 08-06-2025
- GNFT 04-24-2025
- Dividend Yield
- EDIT N/A
- GNFT N/A
- EPS Growth
- EDIT N/A
- GNFT N/A
- EPS
- EDIT N/A
- GNFT 0.03
- Revenue
- EDIT $35,837,000.00
- GNFT $73,187,701.00
- Revenue This Year
- EDIT N/A
- GNFT $15.98
- Revenue Next Year
- EDIT N/A
- GNFT N/A
- P/E Ratio
- EDIT N/A
- GNFT $120.71
- Revenue Growth
- EDIT N/A
- GNFT 105.01
- 52 Week Low
- EDIT $0.91
- GNFT $2.55
- 52 Week High
- EDIT $6.05
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- EDIT 74.64
- GNFT 44.52
- Support Level
- EDIT $2.48
- GNFT $3.44
- Resistance Level
- EDIT $3.24
- GNFT $3.81
- Average True Range (ATR)
- EDIT 0.25
- GNFT 0.17
- MACD
- EDIT 0.07
- GNFT -0.00
- Stochastic Oscillator
- EDIT 84.84
- GNFT 56.65
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.